GPP
Great Point Partners Portfolio holdings
AUM
$154M
This Quarter Return
+5.56%
1 Year Return
-2.36%
3 Year Return
+169.3%
5 Year Return
+292.82%
10 Year Return
+3,519.88%
AUM
$1.11B
AUM Growth
+$1.11B
(-11%)
Cap. Flow
-$162M
Cap. Flow
% of AUM
-14.62%
Top 10 Holdings %
Top 10 Hldgs %
67.44%
Holding
43
New
7
Increased
11
Reduced
15
Closed
9
Top Buys
| 1 |
Aurinia Pharmaceuticals
AUPH
|
$36.6M |
| 2 |
Cytokinetics
CYTK
|
$22.3M |
| 3 |
CCXI
ChemoCentryx, Inc.
CCXI
|
$13.9M |
| 4 |
TBIO
Translate Bio, Inc. Common Stock
TBIO
|
$12.8M |
| 5 |
Allogene Therapeutics
ALLO
|
$12.4M |
Top Sells
| 1 |
Akebia Therapeutics
AKBA
|
$47.7M |
| 2 |
Zymeworks
ZYME
|
$46.9M |
| 3 |
TG Therapeutics
TGTX
|
$46M |
| 4 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
$26.4M |
| 5 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
$22.8M |
Sector Composition
| 1 | Healthcare | 95.89% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CALA
26
DELISTED
Calithera Biosciences, Inc
CALA
| $10.1M | 0.91% |
2,918,581
+656,881
| +29% | +$2.27M |
|
|
KDMN
27
DELISTED
Kadmon Holdings, Inc.
KDMN
| $9.8M | 0.88% |
2,500,000
+1,824,321
| +270% | +$7.15M |
|
|
VRAY
28
DELISTED
ViewRay, Inc.
VRAY
| $9.3M | 0.84% |
2,655,763
-118,048
| -4% | -$413K |
|
29
Lantheus
LNTH
$3.75B
| $7.54M | 0.68% |
+594,750
| New | +$7.54M |
|
30
Liquidia Corp
LQDA
$2.52B
| $5.85M | 0.53% |
1,189,607
-88,348
| -7% | -$435K |
|
31
Abeona Therapeutics
ABEO
$356M
| $3.97M | 0.36% |
3,892,921
-3,320,091
| -46% | -$3.39M |
|
32
Tempest Therapeutics
TPST
$46.6M
| $1.92M | 0.17% |
1,177,900
-282,797
| -19% | -$461K |
|
|
OYST
33
DELISTED
Oyster Point Pharma, Inc. Common Stock
OYST
| $1.48M | 0.13% |
70,121
-144,510
| -67% | -$3.05M |
|
|
XLRN
34
DELISTED
Acceleron Pharma Inc.
XLRN
| – | – |
-58,056
| Closed | -$5.53M |
|
|
MTEM
35
DELISTED
Molecular Templates, Inc.
MTEM
| – | – |
-1,345,397
| Closed | -$18.6M |
|
|
AXNX
36
DELISTED
Axonics, Inc. Common Stock
AXNX
| – | – |
-459,503
| Closed | -$16.1M |
|
37
PTC Therapeutics
PTCT
$4.41B
| – | – |
-330,000
| Closed | -$16.7M |
|
38
NextCure
NXTC
$13.3M
| – | – |
-999,666
| Closed | -$21.4M |
|
39
Neurogene
NGNE
$284M
| – | – |
-14,065
| Closed | -$233K |
|
40
Denali Therapeutics
DNLI
$2.24B
| – | – |
-280,000
| Closed | -$6.77M |
|
41
CytomX Therapeutics
CTMX
$350M
| – | – |
-1,448,604
| Closed | -$12.1M |
|
42
Arvinas
ARVN
$580M
| – | – |
0
| – | – |
|
|
43
Akebia Therapeutics
AKBA
$827M
| – | – |
-3,510,073
| Closed | -$47.7M |
|